Cardiovascular Health

By targeting aldosterone in a 2-dose regimen, baxdrostat effectively lowers mean seated systolic blood pressure in patients with difficult-to-treat hypertension.

Experts discuss groundbreaking Hot Line trials at the European Society of Cardiology Congress 2025, offering insights into the latest cardiovascular research.

A meta-analysis suggests that long-term P2Y12 inhibitor monotherapy after percutaneous coronary intervention may offer superior protection against major adverse cardiac and cerebrovascular events compared with aspirin, without increasing major bleeding risk—potentially challenging current guideline recommendations for antiplatelet therapy beyond 1 year.

Jeffrey I. Weitz, OC, MD, FAHA, FRCPC, FACP, FRSC, FACC, FESC, FCAHS, discusses AZALEA-TIMI 71 trial data showing that the long-acting factor XI inhibitor abelacimab is associated with low periprocedural bleeding risk, supporting potential simplification of anticoagulation protocols for most elective and some urgent procedures.

Finerenone plays an emerging role in managing complex heart failure with preserved ejection fraction (HFpEF).

Results from the ZENITH trial show sotatercept's promise for pulmonary arterial hypertension treatment.

Challenges faced by individuals living with HIV include weight gain, cardiovascular risks, and healthy aging strategies.

Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action.

The COBBRA trial compared bleeding risk with rivaroxaban vs apixaban in patients with acute venous thromboembolism.

The expanded instructions for use labeling expand on the Farawave and Farawave Nav Pulsed Field Ablation (PFA) catheters.

Previously indicated to reduce the risk of end-stage kidney disease, cardiovascular death, and hospitalization for heart failure (HF) in chronic kidney disease, finerenone is now approved for patients with HF directly, offering a new treatment option.

The 2025 National Lipid Association (NLA) Scientific Sessions highlighted a strategic shift toward early, aggressive cardiometabolic intervention, underscoring the vital role of pharmacists in implementing emerging therapies and optimizing cardiovascular risk reduction.

Experts discussed the promising future of pericarditis treatment.

The data emphasize the idea that there are no safe exposure limits as well as the need for guidelines.

New findings question the integrity of ticagrelor's clinical trials, raising safety concerns and impacting its use in cardiovascular care.

Pharmacists can help oversee the treatment process to ensure patients with transthyretin amyloid cardiomyopathy (ATTR-CM) are adhering to tafamidis.

Host Craig Beavers sits down with Kazuhiko Kido, PharmD, a clinical associate professor at the West Virginia University School of Pharmacy, to discuss intravenous iron and its use in patients with heart failure.

Health care professionals are encouraged to educate patients on potential cannabis-related risks to cardiovascular health.

New research reveals that bedtime antihypertensive dosing does not improve cardiovascular outcomes in frail older adults, emphasizing safety over timing.

Diet influences blood pressure, cholesterol levels, and overall heart function.

Host Craig Beavers chats with Shannon Finks, PharmD, FCCP, BCPS, BCCP, AHSCP-CHC, president and director of pharmacy services at ZupMed in Memphis, Tennessee.

Pharmacists play a critical role in managing complex pericarditis cases.

Pharmacists have a unique opportunity to improve cardiovascular outcomes by integrating medication management with food-as-medicine approaches.

The FDA has approved a groundbreaking single-pill combination therapy for hypertension, enhancing cardiovascular health with triple-agent efficacy.

Rilonacept offers a targeted approach to treating recurrent pericarditis by blocking IL-1 inflammatory pathways.